Minimal CYP metabolism (primarily glucuronidation) → fewest drug interactions of any statin. Neutral to slightly favourable glycemic profile (versus the small dysglycemic tendency of other statins) — the main niche.
Half-Life & Elimination Curve (PO: 11h)
Plasma (PO)t½ Decay (11h)
0×t½0h100%(6.64 µg/L)
1×t½11h50%(3.32 µg/L)
2×t½22h25%(1.66 µg/L)
3×t½33h12.5%(0.83 µg/L)
4×t½44h6.3%(0.415 µg/L)
5×t½55h3.1%(0.207 µg/L)
Elimination t½11h (PO)
Rate Constant (ke)0.063 h⁻¹
Time to Peak (Tmax)42m
Est. Peak (Cmax)6.64 µg/L
Clearance (CL)9.26 L/h
97% Washout (5×t½)55h
Dosing Guidelines
Oral (PO): Typical 2 mg (Range: 1–4 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 51% · Volume of Distribution (Vd): 147 L · Absorption (ka): 6.74 h⁻¹ (t½ka ≈ 6m) [PMID 26082816]